Cipla Ltd — Q1 FY26
Cipla reported Q1 FY26 revenue of INR 6,957 crore (+4% YoY) with EBITDA margin of 25.6% (flat YoY) and PAT of INR 1,298 crore (+10.2% YoY).
neutral
medium
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
33%Questions answered6Evaded / deflected12Questions audited
Partial answer
High priority
Outlook for US business growth in FY26 and FY27; timing of Apraxane and Nilotinib launches.
Asked by Kunal Dhamesha, Macquarie
Management gave partial launch timing but did not quantify growth outlook.
no specific growth outlook givenlaunch timing vague
Read the exchange
Question
Our outlook on the US business growth remains for FY 2026 and FY 2027. And were Apraxane and Nilotinib already launched in Q1, or they were launched in July?
Umang Vohra, Global Managing Director and CEO
Launched partially in Q1. We've not launched, the Q1 does not reflect the full momentum of the launch. For Nilotinib and NanoPaclitaxel...
Answered
High priority
Is $1 billion US sales in FY27 still achievable?
Asked by Kunal Dhamesha, Macquarie
Management directly affirmed the target and attributed it to pipeline.
Read the exchange
Question
For aspiration to achieve closer to $1 million sales in the US in FY 2027, we still believe that's possible?
Umang Vohra, Global Managing Director and CEO
Yeah. That's largely out of our pipeline opportunity. We believe that our pipeline should hopefully get us closer or surpass that...
Evasive
High priority
Details on imminent biosimilar launch: partner, product, competitive landscape, economics.
Asked by Kunal Dhamesha, Macquarie
Management deflected by referring to partner disclosure and gave no specifics.
partner name not disclosedproduct name not givenno economics provided
Read the exchange
Question
If you can provide more details on the imminent launch biosimilar... Who is the partner? What product is it? Competitive landscape, supply roles, and the economics...
Umang Vohra, Global Managing Director and CEO
I believe our partner has made a disclosure, and I think the product name is, it's in supportive therapy... It's not a first launch by any player. There are many other players in this category.
Partial answer
Medium priority
Why is branded generic growth muted despite chronic portfolio?
Asked by Kunal Dhamesha, Macquarie
Management explained seasonality and restructuring but did not quantify impact.
no specific growth numbers given
Read the exchange
Question
It seems branded generic has been muted, and within Vespi, shouldn't our portfolio be more chronic with the inhalers, etc., and hence the volatility should be less for us?
Umang Vohra, Global Managing Director and CEO
The impact of the seasons being a little different... respiratory season did not really take off as much... We also strategically aligned our team to further our growth of our triples combination.
Evasive
High priority
Can US sales maintain $226 million annualized run rate in FY26?
Asked by Tushar Manudhane, Motilal Oswal Financial Services
Management did not confirm the run rate and cited uncertainty.
no commitment to run ratedeferred to earlier guidance
Read the exchange
Question
Would we be able to maintain this normalized annualized run rate of $226 million for FY 2026?
Umang Vohra, Global Managing Director and CEO
It's a little indeterminate. It depends on when Revlimid, the impact of Revlimid... we are sticking to what we said at the beginning of the year for an overall US trajectory and growth.
Answered
High priority
Will Advair be a one-edge launch? Dual filing for respiratory products?
Asked by Damayanti Kerai, HSBC
Management confirmed dual filings and gave launch timing for Advair.
Read the exchange
Question
Starting with Advair, will it likely be a one-edge launch or will it go to two-edge? For the remaining launches... have you done dual filing for these products for risk management?
Umang Vohra, Global Managing Director and CEO
Yes. We have done double filings for most of our products from a risk management perspective on the respiratory side. Yes, generic Adcock Ingram, it will obviously, the way we're looking at it, maybe an H2 launch in this year.
Partial answer
Medium priority
Reason for meaningful ramp-up in Albuterol MDI market share.
Asked by Surya Narayan Patra, PhillipCapital
Management attributed to supply recovery but did not quantify competitive factors.
no specific reason for ramp-up given
Read the exchange
Question
We have seen this quarter there is a kind of meaningful ramp-up. Is there any reason that we are seeing a kind of meaningful ramp-up because of the competition factor, or it is some aggression from our side?
Ashish Adukia, Global CFO
We've been on the path of this recovery for almost now, I think, about 12, 13 months or so. Our share had dropped about a year back, and then after that, we have consistently gained the market share. Yeah, it's just maximizing the supplies that we have.
Evasive
High priority
Cipla's GLP-1 plan: cost position, distribution, market reach, TAM.
Asked by Surya Narayan Patra, PhillipCapital
Management gave generic strategy without concrete details on competitive advantages.
no specific strengths or TAM givenstrategy vague
Read the exchange
Question
If you could share what is our strength about this product opportunity and what is our plan? Are we kind of trying to play on the strength of the cost position, or is it the distribution strength, or is it a market reach?
Ashish Adukia, Global CFO
The entire GLP-1 category is more important than just looking at individual products... We are playing a mix and hybrid strategy. At places we are filing, at places we have our own product, as well as we've also got a product from partner's value chain as well.
Partial answer
High priority
Why India growth not better given low base? Will realignment impact future quarters?
Asked by Neha Manpuria, Bank of America
Management acknowledged lower growth but did not quantify realignment impact.
no quantification of realignment impact
Read the exchange
Question
Should not the India growth have been a little better than the industry given the low base in the pre-generic segment? And this repeat realignment... is that likely to impact our growth for a couple of quarters?
Umang Vohra, Global Managing Director and CEO
The growth should have been higher. I think when we isolate the problem... respiratory and acute is almost 59%-58% of the total mix. Unfortunately, this quarter, they have both grown at 4%-5% level.
Declined
High priority
Should margins be higher given US pipeline? Can 23.5% margin be sustained in FY27?
Asked by Neha Manpuria, Bank of America
Management refused to provide margin outlook for FY27.
deferred guidance to year-end
Read the exchange
Question
Shouldn't the margins be higher? ...can we keep margins at 23.5% in fiscal 2027 as well?
Achin Gupta, Global COO
We are a little early for us to give guidance for next year. Closer to the year-end... we'll be in better position to do that.
Evasive
High priority
Will new US launches compensate for Revlimid loss this year?
Asked by Bino Pathiparampil, Elara Capital
Management did not confirm whether FY26 US revenue would match FY25.
no timeline givenno revenue comparison
Read the exchange
Question
From your statement that the new launches in the U.S. will compensate for the loss of generic Revlimid, should we read that this year's total U.S. will be more or less similar to last year's?
Achin Gupta, Global COO
Your launches will come at different timelines. So it's difficult to say in terms of timelines. We have plans for all our launches that are coming in will make up for the revenue loss... That will happen in a short to medium term.
Evasive
High priority
How big will paclitaxel and nilotinib be for Cipla in FY26?
Asked by Saion Mukherjee, Nomura Securities
Management declined to provide any size estimate for the launches.
no revenue estimate given
Read the exchange
Question
The initial market share that you're seeing for the new launches, paclitaxel and nilotinib, if you can share how should we think about how big these two products are likely to be for Cipla in fiscal 2026?
Umang Vohra, Global Managing Director and CEO
I can't give you a ballpark sort of an estimate. I can tell you that the market is big enough to accommodate perhaps more vials than what we can produce.